Propanc Biopharma (PPCB) Shares Outstanding (2020 - 2025)
Propanc Biopharma (PPCB) posted quarterly Shares Outstanding (Entity) of $537988.0 for Q4 2025, up 92656.55% year-over-year from N/an in Q4 2024, and up 5.02% quarter-over-quarter from $512270.0 in Q3 2025.
Propanc Biopharma (PPCB) Shares Outstanding (2020 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Shares Outstanding (Entity) for 6 consecutive years, with $537988.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 92656.55% year-over-year to $537988.0; the TTM figure through Dec 2025 stood at $537988.0 (up 92656.55% YoY), while the FY2025 annual figure was $158727.0, up 233322.06% from the prior year.
- Shares Outstanding (Entity) improved to $537988.0 in Q4 2025 per PPCB's latest filing, from $512270.0 in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $537988.0 in Q4 2025 and bottomed at $1.0 in Q2 2023.
- Historically, Shares Outstanding (Entity) has averaged $69308.2 across 5 years, with a median of $61.5 in 2022.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) slumped 98.18% — and 2025, when it jumped 360400.0%.
- Propanc Biopharma's Shares Outstanding (Entity) stood at $42.0 in 2021, then soared by 1728.57% to $768.0 in 2022, then sank by 97.53% to $19.0 in 2023, then soared by 2952.63% to $580.0 in 2024, then surged by 92656.55% to $537988.0 in 2025.
- Business Quant data shows PPCB's Shares Outstanding (Entity) at $537988.0 in Q4 2025, $512270.0 in Q3 2025, and $158727.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 534,414.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 534,414.00 |
| Sep 30, 2025 | 493,261.00 |
| Jun 30, 2025 | 158,727.00 |
| Mar 31, 2025 | 173,040.00 |
| Dec 31, 2024 | 534.00 |
| Sep 30, 2024 | 473.00 |
| Jun 30, 2024 | 68.00 |
| Mar 31, 2024 | 48.00 |
| Dec 31, 2023 | 19.00 |
| Sep 30, 2023 | 9.00 |
| Jun 30, 2023 | 1.00 |
| Mar 31, 2023 | 1,539.00 |
| Dec 31, 2022 | 768.00 |
| Sep 30, 2022 | 379.00 |
| Jun 30, 2022 | 55.00 |
| Mar 31, 2022 | 53.00 |
| Dec 31, 2021 | 39.00 |
| Sep 30, 2021 | 22.00 |
| Jun 30, 2021 | 2.00 |
| Mar 31, 2021 | 3.00 |